Merck and Institute for Systems Biology Collaborate to Define Molecular Mechanisms of SARS-CoV-2 Infection and Identify Potential Prognostic Biomarkers
KENILWORTH, N.J. & SEATTLE–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the Institute for Systems Biology (ISB), today announced a new research collaboration to investigate and define the molecular mechanisms of SARS-CoV-2 infection and COVID-19 and identify targets for medicines and vaccines. Merck has also entered into an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within an agency of the U.S.
Merck Media:
Patrick Ryan
+1 (201) 452-2409
Ian McConnell
+1 (973) 901-5722
Merck Investors:
Peter Dannenbaum
+1 (908) 740-1037
Michael DeCarbo
+1 (908) 740-1807
ISB Media:
Joe Myxter
+1 (206) 732-2157
[email protected]
